[Importance of a regional observatory of malarial chemoresistance, an emerging public health problem in the Guyanas region].
A regular implementation of prophylactic and therapeutic decision trees was organized on a consensus basis in Cayenne, French Guiana in 1990, 1995 and 2002. The updated recommendations were based on the knowledge of the in vitro chemosensitivity profiles of the local isolates, mainly coming from big rivers (Maroni and Oyapock, frontiers with Suriname and Brazil, respectively; and more recently Approuague). Most of the patients infected by Plasmodium falciparum were followed by the medical staff of the main hospitals (Cayenne and Saint-Laurent) and of the peripheral health centers in remote areas. Consequently the epidemiological situation and evolution of chemoresistance have been widely observed on a long-term (since 1994) basis in the Maroni region. Yet, we have only partial information coming from the Oyapock valley, even though an important (most of the time) illegal immigration has been developing since the 90s' leading to a notable modification of the epidemiological status of malaria in this eastern region, including a regular increase of P. vivax infections. Presently very little P. vivax chloroquine (and mefloquine) resistance has been identified but this result could lead to a real public health problem in a near future. As such, the National Reference Center on Plasmodium Chemoresistance in the French West Indies and Guiana (CNRCP-AG in French) is a unique observatory of malaria chemoresistance in the Guyanese shield which works with research laboratories of the Institut Pasteur, Paris. This network strategy offers a very attractive perspective for applications of modern tools, including the validation of chemoresistance molecular markers, for malaria control at both medical and public health levels. Some examples related to chloroquine and artemether resistance are given.
Esterre
P
P
CNRCP, Institut Pasteur de Guyane, BP6010, Cayenne Cédex, Guyane française.
Volney
B
B
Meynard
J-B
JB
Legrand
E
E
D000818:Animals; D000962:Antimalarials / Q000494:pharmacology* / Q000627:therapeutic use; D004196:Disease Outbreaks; D004351:Drug Resistance / Q000235:genetics; D018432:Drug Resistance, Multiple / Q000235:genetics; D019353:Endemic Diseases; D005602:France; D005616:French Guiana / Q000453:epidemiology; D006172:Guyana / Q000453:epidemiology; D006801:Humans; D007253:Information Centers / Q000458:organization & administration; D007391:International Cooperation; D016778:Malaria, Falciparum / Q000188:drug therapy / Q000453:epidemiology* / Q000469:parasitology; D016780:Malaria, Vivax / Q000188:drug therapy / Q000453:epidemiology* / Q000469:parasitology; D008517:Phytotherapy; D010963:Plasmodium falciparum / Q000187:drug effects* / Q000235:genetics; D010966:Plasmodium vivax / Q000187:drug effects* / Q000235:genetics; D011634:Public Health; D012042:Registries; D013532:Suriname / Q000453:epidemiology
D000962:Antimalarials